ATE531813T1 - System zur überwachung einer bakteriellen tumorbehandlung - Google Patents

System zur überwachung einer bakteriellen tumorbehandlung

Info

Publication number
ATE531813T1
ATE531813T1 AT02806289T AT02806289T ATE531813T1 AT E531813 T1 ATE531813 T1 AT E531813T1 AT 02806289 T AT02806289 T AT 02806289T AT 02806289 T AT02806289 T AT 02806289T AT E531813 T1 ATE531813 T1 AT E531813T1
Authority
AT
Austria
Prior art keywords
treatment
tumor treatment
progress
bacteria
monitoring bacterial
Prior art date
Application number
AT02806289T
Other languages
English (en)
Inventor
Ming Zhao
Xiao-Ming Li
Meng Yang
Mingxu Xu
Ping Jiang
Lingna Li
Original Assignee
Anticancer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anticancer Inc filed Critical Anticancer Inc
Application granted granted Critical
Publication of ATE531813T1 publication Critical patent/ATE531813T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047Green fluorescent protein [GFP]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0063Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0097Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
AT02806289T 2001-12-31 2002-12-31 System zur überwachung einer bakteriellen tumorbehandlung ATE531813T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34569901P 2001-12-31 2001-12-31
PCT/US2002/041822 WO2003057007A2 (en) 2001-12-31 2002-12-31 System for monitoring bacterial tumor treatment

Publications (1)

Publication Number Publication Date
ATE531813T1 true ATE531813T1 (de) 2011-11-15

Family

ID=23356109

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02806289T ATE531813T1 (de) 2001-12-31 2002-12-31 System zur überwachung einer bakteriellen tumorbehandlung

Country Status (9)

Country Link
US (2) US20030161788A1 (de)
EP (1) EP1461449B1 (de)
JP (1) JP4350519B2 (de)
KR (2) KR101142380B1 (de)
CN (2) CN1623001A (de)
AT (1) ATE531813T1 (de)
AU (1) AU2002367319B8 (de)
CA (1) CA2470411C (de)
WO (1) WO2003057007A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030031628A1 (en) * 2001-07-09 2003-02-13 Ming Zhao Imaging infection using fluorescent protein as a marker
EP1281767A3 (de) * 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
CA2470411C (en) * 2001-12-31 2015-07-07 Anticancer, Inc. System for monitoring bacterial tumor treatment
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (de) * 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
CN100562570C (zh) 2003-06-18 2009-11-25 吉恩勒克斯公司 修饰的重组痘苗病毒及其它微生物,及其应用
US7155274B1 (en) 2003-11-21 2006-12-26 Imaging Diagnostic Systems, Inc. Optical computed tomography scanner for small laboratory animals
JP2008504822A (ja) * 2004-06-29 2008-02-21 アンチキャンサー インコーポレーテッド 癌選択的栄養要求株
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
WO2009126189A1 (en) 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US9730968B2 (en) 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
US20130095072A1 (en) * 2010-01-29 2013-04-18 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
US9042967B2 (en) 2008-05-20 2015-05-26 University Health Network Device and method for wound imaging and monitoring
SG182445A1 (en) 2010-01-29 2012-08-30 Anaeropharma Science Inc Transformation plasmid
EP2764119A2 (de) 2011-10-05 2014-08-13 Genelux Corporation Methoden zum nachweis der replikation oder kolonisierung eines biologischen therapiemittels
CN103146626B (zh) * 2013-02-28 2014-12-31 南京华贞生物医药科技有限公司 一种治疗乳腺癌的基因工程菌及其构建方法和应用
CN115919256A (zh) 2014-07-24 2023-04-07 大学健康网络 用于诊断目的的数据的收集和分析

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251384B1 (en) * 1997-04-28 2001-06-26 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
JP2003501391A (ja) * 1999-06-09 2003-01-14 アンチキャンサー, インコーポレイテッド 細菌毒力を制御するためのメチル化のモジュレーター
EP1414499A4 (de) * 1999-10-04 2004-05-06 Vion Pharmaceuticals Inc Nicht invasives tumor-imaging mittels tumorgerichteter bakterien
US20020132318A1 (en) * 2001-01-29 2002-09-19 Ming Zhao Fluorescent proteins
US20030031628A1 (en) * 2001-07-09 2003-02-13 Ming Zhao Imaging infection using fluorescent protein as a marker
EP1281767A3 (de) * 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
CA2470411C (en) * 2001-12-31 2015-07-07 Anticancer, Inc. System for monitoring bacterial tumor treatment
JP2008504822A (ja) * 2004-06-29 2008-02-21 アンチキャンサー インコーポレーテッド 癌選択的栄養要求株

Also Published As

Publication number Publication date
AU2002367319A1 (en) 2003-07-24
EP1461449A2 (de) 2004-09-29
WO2003057007A2 (en) 2003-07-17
CN1623001A (zh) 2005-06-01
US20030161788A1 (en) 2003-08-28
EP1461449B1 (de) 2011-11-02
KR20040078659A (ko) 2004-09-10
CN101869716B (zh) 2013-12-11
EP1461449A4 (de) 2006-05-03
CA2470411C (en) 2015-07-07
AU2002367319B2 (en) 2008-02-28
AU2002367319B8 (en) 2008-03-06
WO2003057007A3 (en) 2003-11-06
CN101869716A (zh) 2010-10-27
JP4350519B2 (ja) 2009-10-21
KR101142380B1 (ko) 2012-05-18
US20090249500A1 (en) 2009-10-01
CA2470411A1 (en) 2003-07-17
KR20110097841A (ko) 2011-08-31
JP2005521648A (ja) 2005-07-21

Similar Documents

Publication Publication Date Title
ATE531813T1 (de) System zur überwachung einer bakteriellen tumorbehandlung
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
NO20060027L (no) Antistoffer mot bindevevsvekstfaktor
MX340275B (es) Metodos, sistema y aparato para la deteccion, diagnostico y tratamiento de trastornos del ritmo biologico.
CY1117030T1 (el) Τροποποιηση της εκφρασης απολιποπρωτεϊνης c-iii
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
TW200519202A (en) Modulation of eIF4E expression
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
MXPA05011470A (es) Metodos para tratar cefalea de senos.
TW200730211A (en) System and method of delivering radiation therapy to a moving region of interest
TW200502385A (en) Modulation of forkhead box o1a expression
TW200716224A (en) Method of indentifying therapeutic targets for the treatment of vulvovaginal atrophy
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
EA201891507A1 (ru) Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе
BR0206251A (pt) Métodos para avaliar e tratar leucemia
PL1778833T3 (pl) Sposoby stosowania komórek regeneracyjnych w celu przyspieszania gojenia się ran
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
TW200507840A (en) Method of treating multiple myeloma
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
MX2021009247A (es) Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
ATE478942T1 (de) Verfahren zur verwendung regenerativer zellen bei der behandlung von nierenkrankheiten und störungen